Dicerna Inks Drug Discovery and Development Agreement Targeting Liver Disease

Dicerna Inks Dug Discovery and Development Agreement Targeting Liver Disease

Dicerna’s GalXC RNAi platform technology was involved in yet another big pharma collaborative drug discovery and development deal. Just weeks after the announcement of a $1.67 billion deal with Roche, now Novo Nordisk inked an agreement to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases.  With a $175 million upfront payment and an equity infusion of $50 million, not to mention $25 million per year for three years based on certain deliverables, Dicerna commits to collaborate on over 30 liver-cell targets with the goal of delivering multiple clinical candidates. With the ability to inhibit hepatocyte targets involved in disease regulation, the prospect of new clinical development candidates involving chronic liver disease (e.g. non-alcoholic steatohepatitis or “NASH”, type 2 diabetes, obesity and others) fits in Novo Nordisk’s growth hypothesis. Can Dicerna leverage its existing resources to achieve its own pipeline as well as meet the conditions required from the Bagsvaerd-based company?

Innovation via Collaboration

In what is becoming a familiar story with big pharma, juggernauts such as Novo Nordisk increasingly look to...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee